ReviewJournal of microbiology and biotechnology2022
Leaky Gut in IBD: Intestinal Barrier-Gut Microbiota Interaction.
Review in Journal of microbiology and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 113 citations in OpenAlex.
- Glutamine Peptides: Preparation, Analysis, Applications, and Their Role in Intestinal Barrier Protection.Nutrients · 2025Pooled it
- Article
- Microplastics and nanoplastics in inflammatory bowel disease: Mechanistic plausibility, human evidence and future research priorities.World journal of gastrointestinal pathophysiology · 2026Review
- The potency of native postbiotics and paraprobiotics in modulating inflammation by affecting the gut-kidney axis.Animal models and experimental medicine · 2026Article
- Review
- Body mass index and gastrointestinal inflammation: Bio-molecular pathophysiology.World journal of gastrointestinal pathophysiology · 2026Review
- Unraveling the gut microbiota-brain axis: Mechanisms, pathophysiology, and therapeutic opportunities.iScience · 2026Review
- Targeting the Human Gut Microbiota-Between Conventional Therapy and Precision Genetic Engineering.Nutrients · 2026Review
- Metagenomic Profiling of the Gut Microbiome in Age-Related Macular Degeneration-A Pilot Study.Biomedicines · 2026Article
- Extra-Virgin Olive Oil Phenolics in IBD-Associated Vascular Risk.Molecules (Basel, Switzerland) · 2026Review
- Personalized barrier recovery induced by Lactobacillus helveticus SBT2171 in an In Vitro model of ulcerative colitis-derived fecal supernatants.BMC complementary medicine and therapies · 2026Article
- Article
- Rising Tide of Crustacean Allergies in East Asia: a Comprehensive Review of Genetic Insights and Implications for Early Evaluation of Health Risks.Clinical reviews in allergy & immunology · 2026Review
- Prenatal supplementation with the gut-derived tryptophan metabolite indole-3-propionic acid alleviates colitis susceptibility in maternal immune-activated offspring mice.Journal of advanced research · 2026Article
- Harnessing Anthocyanins to Mitigate Inflammation, Dysbiosis, and Aging in the Gastrointestinal Tract.ACS pharmacology & translational science · 2026Review
- Silent Intruders: The Gut Virome in Brain Aging and Cognitive Decline.Pathogens (Basel, Switzerland) · 2026Review
- Qing-Chang-Hua-Shi granule ameliorates experimental colitis by modulating Lactobacillus gasseri-mediated ferroptosis metabolic pathway.Chinese medicine · 2026Article
- Dual-pathway mechanisms of plant-derived polysaccharides in ulcerative colitis: integrative roles of microbiota modulation, immune regulation, and barrier restoration.Frontiers in pharmacology · 2026Review
- Mechanistic evidence and assumptions in mycotoxin-gut interaction.Frontiers in fungal biology · 2026Article
- Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn's disease.Frontiers in immunology · 2026Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a global disease that is in increasing incidence. The gut, which contains the largest amount of lymphoid tissue in the human body, as well as a wide range of nervous system components, is integral in ensuring intestinal homeostasis and function. By interacting with gut microbiota, immune cells, and the enteric nervous system, the intestinal barrier, which is a solid barrier, protects the intestinal tract from the external environment, thereby maintaining homeostasis throughout the body. Destruction of the intestinal barrier is referred to as developing a "leaky gut," which causes a series of changes relating to the occurrence of IBD. Changes in the interactions between the intestinal barrier and gut microbiota are particularly crucial in the development of IBD. Exploring the leaky gut and its interaction with the gut microbiota, immune cells, and the neuroimmune system may help further explain the pathogenesis of IBD and provide potential therapeutic methods for future use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.